Literature DB >> 2917193

Thalassemia intermedia resulting from a mild beta-thalassemia mutation.

M C Rosatelli1, L Oggiano, G Battista Leoni, T Tuveri, A Di Tucci, M T Scalas, F Dore, P Pistidda, A Massa, M Longinotti.   

Abstract

We investigated the molecular basis for a mild phenotype in a group of patients with beta(+) thalassemia originating from Northern Sardinia by definition of the beta-thalassemia mutation, alpha-globin mapping and beta-globin haplotype determination. In nine patients, we detected the compound heterozygous state for the -87 promoter mutation and the codon 39 nonsense mutation; in one patient, we detected the combination of the codon 39 nonsense mutation and beta(+) IVS-1 nt 6 mutation. These patients were either nontransfusion dependent for survival or became transfusion dependent later. We did not detect the -87 promoter mutation in any of 115 thalassemia major patients originating from the same part of Sardinia, investigated as controls. Heterozygotes for the -87 promoter mutation showed statistically higher hemoglobin (Hb) levels and larger and better hemoglobinized RBCs as compared with heterozygotes for the codon 39 nonsense mutation. From these data, we conclude that the -87 promoter mutation is a mild thalassemia allele, able to produce a phenotype of intermediate severity even in combination with a beta(0)-thalassemia mutant. The coinheritance of alpha-thalassemia or the -++-- 5' subhaplotype in several cases may have contributed to development of the mild clinical picture. Characterization of the beta-thalassemia mutation in combination with alpha-globin mapping and haplotype analysis may allow a better estimate of the probability of a given clinical phenotype, thus permitting more accurate counseling.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2917193

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Effect of alpha thalassaemia trait and enhanced gamma chain production on disease severity in beta thalassaemia major and intermedia.

Authors:  P Gringras; B Wonke; J Old; A Fitches; D Valler; A M Kuan; V Hoffbrand
Journal:  Arch Dis Child       Date:  1994-01       Impact factor: 3.791

2.  Altered regulation of beta-like globin genes by a redesigned erythroid transcription factor.

Authors:  Deepa Manwani; Mariann Galdass; James J Bieker
Journal:  Exp Hematol       Date:  2007-01       Impact factor: 3.084

3.  Percentile curves for red cell indices of beta zero-thalassaemia heterozygotes in infancy and childhood.

Authors:  R Galanello; F Lilliu; F Bertolino; A Cao
Journal:  Eur J Pediatr       Date:  1991-04       Impact factor: 3.183

4.  Thalassemia intermedia: compound heterozygous beta zero/beta(+)-thalassemia and co-inherited heterozygous alpha(+)-thalassemia.

Authors:  A E Kulozik; E Kohne; E Kleihauer
Journal:  Ann Hematol       Date:  1993-01       Impact factor: 3.673

5.  Evolution of a genetic disease in an ethnic isolate: beta-thalassemia in the Jews of Kurdistan.

Authors:  D Rund; T Cohen; D Filon; C E Dowling; T C Warren; I Barak; E Rachmilewitz; H H Kazazian; A Oppenheim
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

6.  A Novel -72 (T→A) β-Promoter Mutation Causing Slightly Elevated HbA2 in a Vietnamese Heterozygote.

Authors:  Monica Pirastru; Paolo Mereu; Chau Quynh Nguyen; Nhan Viet Nguyen; Thang Duy Nguyen; Laura Manca
Journal:  Biomed Res Int       Date:  2017-04-19       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.